SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis
- 1 April 2001
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 144 (4) , 788-794
- https://doi.org/10.1046/j.1365-2133.2001.04134.x
Abstract
Background SDZ ASM 981 is a selective inhibitor of the production of pro‐inflammatory cytokines from T cells and mast cells in vitro. It is the first ascomycin macrolactam derivative under developme...Keywords
This publication has 8 references indexed in Scilit:
- A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacologyBritish Journal of Dermatology, 1999
- Executive Committee ReportJournal of the European Academy of Dermatology and Venereology, 1999
- Eczema area and severity index (EASI): A new tool to evaluate atopic dermatitisJournal of the European Academy of Dermatology and Venereology, 1998
- Low systemic concentrations of SDZ ASM 981 after topical treatment of extensive atopic dermatitis lesionsJournal of the European Academy of Dermatology and Venereology, 1998
- Effectiveness of the Ascomycin Macrolactam SDZ ASM 981 in the Topical Treatment of Atopic DermatitisArchives of Dermatology, 1998
- A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases:in vivopharmacologyBritish Journal of Dermatology, 1997
- Pathogenesis of atopic eczemaThe Lancet, 1994
- Diagnostic Features of Atopic DermatitisActa Dermato-Venereologica, 1980